0
0
May 1, 2025 – In a significant advancement for patients with generalized myasthenia gravis (gMG), the US Food and Drug Administration (FDA) has approved nipocalimab-aahu (brand name Imaavy, developed by Johnson & Johnson) for the treatment of adults and adolescents aged 12 and older. This approval marks the arrival of the first and only human Fc receptor (FcRn)-blocking monoclonal antibody for patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific-kinase (anti-MuSK) antibody positive.
A Milestone in gMG Management
Nipocalimab-aahu will be supplied as a single-dose vial for intravenous injection. The FDA’s decision follows a Priority Review designation and is based on compelling results from the phase 3 Vivacity-MG3 trial. In this study, patients treated with nipocalimab-aahu alongside standard care experienced notably better disease control over a 24-week period, as measured by the Myasthenia Gravis-Activities of Daily Living (MG-ADL) assessment, compared to those receiving placebo.
These benefits were not only rapid but also sustained, with improvements maintained for up to 20 months in an ongoing open-label extension study. The active treatment group demonstrated a “rapid and sustained reduction in autoantibody levels by up to 75% from the first dose,” according to Johnson & Johnson.
Dr. Nicholas J. Silvestri, professor of neurology at the University of Buffalo, commented, “The clinical results we’ve seen with Imaavy represent a significant milestone in the treatment of gMG. Having a treatment that delivers this level of durable symptom stability is a meaningful step forward for managing a complex and unpredictable disease like gMG.”
Pediatric Data and Patient Support
Additional data from the ongoing Vibrance phase 2/3 pediatric study showed that adolescents aged 12–17 who were anti-AChR and anti-MuSK antibody positive experienced a 69% reduction in total serum immunoglobulin G levels over 24 weeks, with corresponding improvements in MG-ADL scores.
To support patient access, Johnson & Johnson announced a US-based program that may allow insured patients to receive their first prescribed treatment in as little as one week and potentially pay as little as $0 per infusion.
Safety Profile
The most common serious treatment-related adverse events reported were possible infections, allergic reactions, and infusion-related reactions. Other potential side effects include respiratory tract infections, muscle spasms, and swelling in the hands, ankles, and feet.
Disclaimer:
This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Please consult your healthcare provider for guidance specific to your health condition. The information is based on a press release and clinical trial data as of May 2025; ongoing research may provide additional insights.
Citations:
